PSTI - Pluristem Therapeutics Inc.
| Previous Close | 1.24 |
| Open | 1.23 |
| Bid | 1.10 x 3000 |
| Ask | 1.28 x 1000 |
| Day's Range | 1.19 - 1.23 |
| 52 Week Range | 1.06 - 2.12 |
| Volume | 103,248 |
| Avg. Volume | 297,250 |
| Market Cap | 133.042M |
| Beta | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.31 |
| Earnings Date | Feb 15, 2018 - Feb 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.83 |
- GlobeNewswire•27 days ago
Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board
HAIFA, Israel, March 26, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Dr. Roger Jeffs has joined Pluristem’ s strategic advisory ...
- GlobeNewswire•2 months ago
Pluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine
HAIFA, Israel, Feb. 27, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Frontiers in Medicine has published key findings from a study ...
- Simply Wall St.•2 months ago
What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors
I am going to take a deep dive into Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...
- GlobeNewswire•2 months ago
Pluristem Issues Letter to Shareholders
HAIFA, Israel, Feb. 07, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today reported financial results for the second quarter of fiscal 2018 ended December ...
- Reuters•3 months ago
N.Korea threats spur U.S. search for new radiation therapies
The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome. The hostility between the two nations reached a new height last November after Pyongyang fired an intercontinental ballistic missile capable of reaching the U.S. mainland. The DoD's budget allocated $3.9 million of its total funding to develop such medical countermeasures in 2018, an increase of $600,000 from a year ago.
- ACCESSWIRE•3 months ago
Wired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article
Stock Monitor: CEL-SCI Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 17, 2018 / Active-Investors.com has just released a free research report on Pluristem Therapeutics Inc. (NASDAQ: PSTI ). ...
- Simply Wall St.•4 months ago
Does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Past Performance Indicate A Weaker Future?
Assessing Pluristem Therapeutics Inc’s (NASDAQ:PSTI) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
- ACCESSWIRE•4 months ago
Wired News – VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells
Stock Monitor: Pluristem Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 12, 2017 / Active-Investors issued a free report on VistaGen Therapeutics Inc. (NASDAQ: VTGN ) ("VistaGen"), ...
- Simply Wall St.•5 months ago
Is It Time To Buy Pluristem Therapeutics Inc (PSTI)?
Pluristem Therapeutics Inc (NASDAQ:PSTI), a biotechnology company based in Israel, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...
- Associated Press•5 months ago
Pluristem reports 1Q loss
On a per-share basis, the Haifa, Israel-based company said it had a loss of 8 cents. In the final minutes of trading on Tuesday, the company's shares hit $1.47. A year ago, they were trading at $1.51. ...
- ACCESSWIRE•6 months ago
Today's Research Reports on Trending Tickers: Athersys and Pluristem Therapeutics
NEW YORK, NY / ACCESSWIRE / October 12, 2017 / All three major indexes closed at record highs Wednesday after minutes from the most recent Federal Reserve Meeting suggested a December rate hike was not ...
- Zacks•6 months ago
Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1%
Pluristem Therapeutics Inc. (PSTI) saw its shares rise over 5% on the day.
- ACCESSWIRE•7 months ago
Earnings Review and Free Research Report: Pluristem Announced Fiscal 2017 Results
LONDON, UK / ACCESSWIRE / September 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Pluristem Therapeutics Inc. (NASDAQ: PSTI ) ("Pluristem"), which can be viewed ...
- ACCESSWIRE•7 months ago
Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP
Research Desk Line-up: Pluristem Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...
- Zacks•7 months ago
Pluristem's Ischemia Candidate Gets Fast Track Designation
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
